Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 6Thoracic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 17Triple Negative Breast Neoplasms 13Ovarian Neoplasms 2Breast Cancer Metastatic 2Uterine Cervical Neoplasms 1Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer 1Stomach Neoplasms 1Neoplasms 1HR+/HER2-breast Cancer 1HER2-negative Breast Cancer Brain Metastases 1Fludzoparib" and Anti-angiogenic 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Organoids 1Advanced Triple-Negative Breast Cancer 1Advanced Triple Negative Breast Cancer 1Advanced Breast Cancer 1

Interventions

pembrolizumab 24Nivolumab 7Early Intervention, Educational 7Methods 6durvalumab 5aldesleukin 5Trastuzumab 5Paclitaxel 5Fulvestrant 5Carboplatin 5atezolizumab 4Surveys and Questionnaires 4Patient Navigation 4Docetaxel 4Cyclophosphamide 4Biopsy 4fludarabine 3Mass Screening 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Interleukin-2 3Gene Expression Profiling 3Fluorouracil 3Educational Status 3Bevacizumab 3tremelimumab 2spartalizumab 2sargramostim 2palbociclib 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × apatinib × Breast × Clear all
NCT03384511 2018-02-20

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

Shandong Cancer Hospital and Institute

Phase 4 Completed
38 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡